Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abcellera Biologics Inc
(NQ:
ABCL
)
2.720
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
216
Open
2.720
Bid (Size)
2.630 (15)
Ask (Size)
2.720 (5)
Prev. Close
2.720
Today's Range
2.720 - 2.720
52wk Range
2.335 - 6.055
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AbCellera to Present at Upcoming Investor Conferences in December and January
November 21, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
November 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Performance
YTD
-52.53%
-52.53%
1 Month
-4.23%
-4.23%
3 Month
+8.37%
+8.37%
6 Month
-29.35%
-29.35%
1 Year
-38.60%
-38.60%
More News
Read More
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
November 04, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AbCellera Reports Q3 2024 Business Results
November 04, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
October 22, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
October 04, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
September 26, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
September 15, 2024
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
September 10, 2024
Via
Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
September 05, 2024
Via
Talk Markets
Topics
Economy
Exposures
Economy
AbCellera to Present at Upcoming Investor Conferences in September
August 29, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
August 27, 2024
Via
Talk Markets
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
August 20, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
Via
Talk Markets
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
August 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AbCellera Reports Q2 2024 Business Results
August 06, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 31, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
Via
Talk Markets
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday
July 28, 2024
Via
Talk Markets
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
Via
The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
Via
Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
July 02, 2024
Via
Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 25, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.